Search hospitals
>
New Mexico
>
Las Cruces
Memorial Medical Center - Las Cruces
Claim this profile
Las Cruces, New Mexico 88011
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
108 reported clinical trials
13 medical researchers
Summary
Memorial Medical Center - Las Cruces is a medical facility located in Las Cruces, New Mexico. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Memorial Medical Center - Las Cruces is involved with conducting 108 clinical trials across 260 conditions. There are 13 research doctors associated with this hospital, such as Atul Kumar, Carolyn Y. Muller, Ursa A. Brown-Glaberman, and Neda Hashemi Sadraei.
Area of expertise
Breast Cancer
Memorial Medical Center - Las Cruces has run 29 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Memorial Medical Center - Las Cruces has run 24 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Atul Kumar
University of New Mexico Cancer Center
5 years of reported clinical research
Carolyn Y. Muller
University of New Mexico Cancer Center
1 year of reported clinical research
Ursa A. Brown-Glaberman
University of New Mexico Cancer Center
6 years of reported clinical research
Neda Hashemi Sadraei
University of New Mexico Cancer Center
5 years of reported clinical research
Clinical Trials running at Memorial Medical Center - Las Cruces
Lung Cancer
Breast Cancer
Cancer
Colorectal Cancer
Bladder Cancer
Lymphoma
Pancreatic Cancer
Prostate Cancer
Multiple Myeloma
Chronic Lymphocytic Leukemia
High-Dose Radiation + Chemotherapy and Immunotherapy
for Non-Small Cell Lung Cancer
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting
2 awards
Phase 3
14 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Blood Sample Collection
for Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.
Recruiting
1 award
N/A
9 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Memorial Medical Center - Las Cruces?
Memorial Medical Center - Las Cruces is a medical facility located in Las Cruces, New Mexico. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Memorial Medical Center - Las Cruces is involved with conducting 108 clinical trials across 260 conditions. There are 13 research doctors associated with this hospital, such as Atul Kumar, Carolyn Y. Muller, Ursa A. Brown-Glaberman, and Neda Hashemi Sadraei.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.